None
Conditions
Interventions
Control group:The initial dose is 2mg/kg until the revised vigilance and sedation score (MOAA/S) is less than or equal to 1 point. If the BIS is higher than 60, the supplementary dose is 0.5mg/kg
Experimental group:The initial dose is 10mg/kg until the revised vigilance and sedation score (MOAA/S) is less than or equal to 1 point. If the BIS is higher than 60, the supplementary dose is 2mg/kg
Sponsors
Zhongshan Hospital,Fudan University(Xiamen Branch)
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Patients who are scheduled to undergo hysteroscopy or surgery; 2. American Medical Association (ASA) classification I to III; 3. Age: 18 -65 years old 4. The hysteroscopic operation time is less than 1 hour (h). 5. Body Mass Index (BMI) <30kg/m ².
Exclusion criteria
Exclusion criteria: 1. Abnormal liver and kidney functions: total bilirubin >3 times the upper limit or alanine aminotransferase and aspartate aminotransferase >5 times the upper limit ?, elevated serum creatinine >=3 times the baseline value; 2. Sinus bradycardia (HR<50bpm), atrioventricular block; 3. Preoperative hypotension (systolic blood pressure <90mmHg); 4. Preoperative hypoxia (SpO2<90%); 5. There was cognitive dysfunction before the operation; 6. Mental and psychological disorders; 7. Alcohol and drug abuse; 8. Drug allergies involved in this experiment; 9. The patient himself/herself refused to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body movement incidence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reaction incidence rate; | — |
Countries
China
Contacts
Public ContactPeiling Cai
Zhongshan Hospital,Fudan University(Xiamen Branch)
Outcome results
None listed